Latest News and Press Releases

Attached is today's presentation held in relation to Vistin Pharma's Capital Markets Day at the Metformin manufacturing plant in Kragerø. Attachment Capital Markets...

Magnus Tolleshaug, Chief Commercial Officer in Vistin Pharma ASA, and a primary insider, has on 31st of May 2023 purchased 15.000 shares in Vistin Pharma ASA at an average price of NOK 24,01 per...

Ferncliff Listed DAI AS has on 30 May 2023 purchased 250,000 shares in Vistin Pharma ASA at NOK 23.12 per share. After the transaction Ferncliff Listed DAI AS has a holding of 1,034,280 shares,...

Oslo, Norway, 22 May 2023 Vistin Pharma ASA (OSE: VISTIN): Please find attached the minutes from the Annual General Meeting held today, on the 22 May 2023. All matters were resolved as proposed...

In relation to the Annual General Meeting in Vistin Pharma ASA on the 22nd of May, the Company's Chair of the Board, Øyvin Brøymer, has received open proxies to represent a total of 3 905 611 shares...

Vistin Pharma will host a Capital Markets Day (CMD) for all interested parties on the 14th of June at its production plant in Stuttlidalen 4 at Fikkjebakke in Kragerø. The invitation is attached. ...

Oslo, Norway, 28 April 2023 Vistin Pharma ASA (OSE: VISTIN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 22 May at 13:00 CEST. A physical Annual...

Oslo, Norway, 27 April 2023 Please find attached the Annual Report for 2022 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full year...

Oslo, Norway, 27th of April 2023 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the first quarter of 2023. Revenue in the first quarter ended at MNOK 101...

Oslo, Norway, 20 April 2023 Vistin Pharma ASA will release its first quarter 2023 results on Thursday 27th of April 2023. Vistin Pharma will host a conference call for all shareholders and...